Endo Pharmaceuticals Holdings Inc. (ENDP) said that its partners, Teikoku Seiyaku Co. Ltd. and Teikoku Pharma USA Inc. have received a Paragraph IV Certification Notice from Watson Laboratories Inc. (WPI) regarding the filing of an abbreviated new drug application for a generic version of Lidoderm.
Lidoderm is a topical patch to relieve the pain of postherpetic neuralgia launched in 1999. Its patent is listed in the FDA's Orange Book and expires in October 2015.
The company said it is currently reviewing the details of this notice from Watson. Endo intends to vigorously defend Lidoderm's intellectual property rights and pursue all available legal and regulatory pathways in defense of Lidoderm.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.